98 related articles for article (PubMed ID: 37536025)
1. Effectiveness of Kabasura Kudineer tablets in the management of asymptomatic and mild cases of COVID-19: A pilot double-blinded, randomized controlled trial.
Khapre M; Pathania M; Saxena V; Omar BJ; Goyal B; Sinha S; Bahurupi Y; Dhamija P
J Ayurveda Integr Med; 2023; 14(4):100777. PubMed ID: 37536025
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients-a double-blind, placebo-controlled, clinical trial.
Srivastava A; Rengaraju M; Srivastava S; Narayanan V; Gupta V; Upadhayay R; Kumar J; Parameswaran S; KanakavalliKadarkarai ; AarthiVelmurugan
Trials; 2021 Aug; 22(1):570. PubMed ID: 34454572
[TBL] [Abstract][Full Text] [Related]
3. A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients - a structured summary of a study protocol for a randomized controlled trial.
Srivastava A; Rengaraju M; Srivastava S; Narayan V; Gupta V; Upadhayay R
Trials; 2021 Feb; 22(1):130. PubMed ID: 33573696
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary of a study protocol for a randomised controlled trial.
Natarajan S; Anbarasi C; Sathiyarajeswaran P; Manickam P; Geetha S; Kathiravan R; Prathiba P; Pitchiahkumar M; Parthiban P; Kanakavalli K; Balaji P
Trials; 2020 Oct; 21(1):892. PubMed ID: 33109252
[TBL] [Abstract][Full Text] [Related]
5. Attitudes, beliefs, and self-use of Kabasura Kudineer among urban and rural population in Tamil Nadu, India: A comparative cross-sectional study.
Bala D
J Family Med Prim Care; 2021 Jan; 10(1):158-166. PubMed ID: 34017720
[TBL] [Abstract][Full Text] [Related]
6. Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled, comparative, randomized controlled trial, Tamil Nadu, India.
Natarajan S; Anbarasi C; Sathiyarajeswaran P; Manickam P; Geetha S; Kathiravan R; Prathiba P; Pitchiahkumar M; Parthiban P; Kanakavalli K; Balaji P
Trials; 2021 Sep; 22(1):623. PubMed ID: 34526104
[TBL] [Abstract][Full Text] [Related]
7. Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach.
Thirumal Kumar D; Shree Devi MS; Udhaya Kumar S; Sherlin A; Mathew A; Lakshmipriya M; Sathiyarajeswaran P; Gnanasambandan R; Siva R; Magesh R; George Priya Doss C
Adv Protein Chem Struct Biol; 2022; 129():275-379. PubMed ID: 35305722
[TBL] [Abstract][Full Text] [Related]
8. Antidiabetic activity of Kabasura Kudineer Chooranam.
Harini P; Veeraraghavan VP; Selvaraj J; Gayathri R; Kavitha S
J Adv Pharm Technol Res; 2022 Dec; 13(Suppl 2):S383-S386. PubMed ID: 36798575
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking analysis of potential compounds from an Indian medicinal soup "kabasura kudineer" extract with IL-6.
Saleem Basha S; Tripathi D; Koora S; Satyanarayana K; Jayaraman S
Bioinformation; 2020; 17(5):568-572. PubMed ID: 35095231
[TBL] [Abstract][Full Text] [Related]
12. The GC-MS Analysis of Kabasura Kudineer: A Vital Siddha Drug in COVID-19 Therapy.
Sudhan A; Prabhu K; Jones S; Balakrishnan D; Muttevi HK; Kalaivannan J
J Pharm Bioallied Sci; 2024 Apr; 16(Suppl 2):S1821-S1823. PubMed ID: 38882785
[TBL] [Abstract][Full Text] [Related]
13. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of a Siddha Medicine fixed regimen for the treatment of asymptomatic and mild COVID-19 patients.
Kannan M; Sathiyarajeswaran P; Sasikumar D; Geetha A; Mohanapriya M; Vinod NP; Manickam P; Kanakavalli K; Parthibhan P; Pitchiah Kumar M; Kannan R; Sivaraman G
J Ayurveda Integr Med; 2022; 13(3):100589. PubMed ID: 35634543
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
16. Computational Study on the Inhibitory Effect of Natural Compounds against the SARS-CoV-2 Proteins.
Jayaraj JM; Jothimani M; Palanisamy CP; Pentikäinen OT; Pannipara M; Al-Sehemi AG; Muthusamy K; Gopinath K
Bioinorg Chem Appl; 2022; 2022():8635054. PubMed ID: 35340421
[TBL] [Abstract][Full Text] [Related]
17. Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CL
Vincent S; Arokiyaraj S; Saravanan M; Dhanraj M
Front Mol Biosci; 2020; 7():613401. PubMed ID: 33425994
[TBL] [Abstract][Full Text] [Related]
18. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
20. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
